Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial

Abstract Background The management of locally advanced prostate cancer (PCa) and oligometastatic prostate cancer (OMPCa) remains a clinical challenge. The heterogeneous nature of PCa prompts a need for precision treatment. This study aims to verify whether genomic biomarker-guided neoadjuvant therap...

Full description

Saved in:
Bibliographic Details
Main Authors: Haichao Huang, Tao Wang, Wei Li, Zhun Wu, Xuegang Wang, Jinchun Xing, Bin Chen, Kaiyan Zhang
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Cancer
Subjects:
Genomic biomarker-guided
Neoadjuvant therapy
Locally advanced
Oligometastatic
Prostate cancer
Online Access:https://doi.org/10.1186/s12885-025-13826-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13826-5

Similar Items